Roche unit Genentech's Polivy, or polatuzumab vedotin-piiq, has been approved by the FDA for use in combination with bendamustine and rituximab as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma who have had two or more previous therapies.
Roche's diffuse large B-cell lymphoma drug gains FDA approval
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.